Annexon Q2 net loss $37.1M; cash $177.6M, extended runway into H2 2025 via $130M private placement

Annexon, Inc.

2022-Q2 EPS reported -$1.88

Net loss of $37.1M ($0.96/share) vs. $31.3M ($0.82/share) in Q2 2021.
Cash and short-term investments $177.6M at June 30, 2022, plus $130M from July private placement.
Operating runway extended into second half of 2025.
FDA granted Fast Track designation to ANX007 for geographic atrophy; Phase 2 enrolled.
Phase 1 trials initiated for oral small molecule ANX1502 and next-gen mAb ANX105.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.